Stockscreener 앱 받기
72.66
0.22%
-0.16
전일 마감가:
$72.82
열려 있는:
$72.82
하루 거래량:
1.30M
Relative Volume:
0.59
시가총액:
$8.54B
수익:
$947.36M
순이익/손실:
$392.47M
주가수익비율:
24.06
EPS:
3.02
순현금흐름:
$392.71M
1주 성능:
+3.43%
1개월 성능:
+9.84%
6개월 성능:
+33.22%
1년 성능:
+52.04%
1일 변동 폭
$72.17
$74.25
1주일 범위
$68.09
$74.25
52주 변동 폭
$46.26
$79.50
Halozyme Therapeutics Inc Stock (HALO) Company Profile
명칭
Halozyme Therapeutics Inc
전화
(858) 794-8889
주소
12390 EL CAMINO REAL, SAN DIEGO, CA
HALO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
72.66 | 8.56B | 947.36M | 392.47M | 392.71M | 3.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.17 | 109.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.61 | 82.75B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
445.12 | 56.78B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
917.63 | 56.52B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.51 | 44.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-14 | 업그레이드 | Leerink Partners | Underperform → Market Perform |
| 2025-08-06 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-10 | 재개 | Goldman | Neutral |
| 2025-05-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | 다운그레이드 | Leerink Partners | Market Perform → Underperform |
| 2024-10-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-09-19 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-06-07 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-02-29 | 개시 | TD Cowen | Outperform |
| 2023-07-24 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-07-24 | 개시 | H.C. Wainwright | Buy |
| 2023-05-10 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | 재개 | Berenberg | Buy |
| 2023-03-16 | 다운그레이드 | SVB Securities | Outperform → Market Perform |
| 2022-12-21 | 재개 | Morgan Stanley | Overweight |
| 2022-11-28 | 개시 | Wells Fargo | Overweight |
| 2022-09-09 | 개시 | Morgan Stanley | Overweight |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2021-06-14 | 개시 | Evercore ISI | Outperform |
| 2021-05-17 | 개시 | SVB Leerink | Outperform |
| 2021-05-11 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-01-21 | 재확인 | The Benchmark Company | Buy |
| 2020-12-17 | 개시 | Berenberg | Buy |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-07-01 | 개시 | The Benchmark Company | Buy |
| 2020-02-05 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2020-01-09 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-08 | 개시 | Goldman | Buy |
| 2019-11-05 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2018-10-19 | 재개 | Piper Jaffray | Neutral |
| 2018-05-11 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2018-01-24 | 개시 | Goldman | Neutral |
| 2017-10-16 | 재확인 | Piper Jaffray | Overweight |
| 2017-01-06 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2016-11-03 | 개시 | Deutsche Bank | Buy |
| 2015-12-04 | 개시 | Wells Fargo | Outperform |
| 2015-11-18 | 개시 | Citigroup | Buy |
| 2015-09-22 | 개시 | Barclays | Overweight |
| 2015-06-22 | 재확인 | JP Morgan | Overweight |
| 2015-03-03 | 재확인 | UBS | Buy |
| 2015-02-18 | 재확인 | MLV & Co | Buy |
| 2015-01-08 | 재확인 | MLV & Co | Buy |
모두보기
Halozyme Therapeutics Inc 주식(HALO)의 최신 뉴스
This Biotech Stock Is Up 50% in 2025, But Redditors Say It Has More Upside – Here’s Why - Yahoo Finance
US Stocks Recap: Why Halozyme Therapeutics Inc. stock could see breakout soon2025 Sector Review & Technical Pattern Based Buy Signals - BỘ NỘI VỤ
Take Profit: Is Halozyme Therapeutics Inc. stock positioned for digital transformationWeekly Trend Report & Smart Investment Allocation Tips - BỘ NỘI VỤ
United StatesCahill Represents Lead Arrangers In Halozyme Therapeutics’ $750 Million Credit Facility - Mondaq
Halozyme to Participate in the 8th Annual Evercore Healthcare Conference - PR Newswire
Halozyme Therapeutics announces CFO transition agreement with Nicole LaBrosse By Investing.com - Investing.com Nigeria
Halozyme Announces CFO Transition Plan - TipRanks
Halozyme Therapeutics announces CFO transition agreement with Nicole LaBrosse - Investing.com
[8-K] HALOZYME THERAPEUTICS, INC. Reports Material Event | HALO SEC FilingForm 8-K - Stock Titan
Halozyme Beats on Q3 Earnings & Revenues, Raises 2025 View - MSN
Halozyme Acquires Drug Delivery Company Elektrofi - CHEManager
Quick ratio of Halozyme Therapeutics, Inc. – HAM:RV7 - TradingView
Is Halozyme Therapeutics Inc. (RV7) stock good for long term investingJuly 2025 PreEarnings & Precise Buy Zone Identification - newser.com
A Look at Halozyme Therapeutics (HALO) Valuation Following New Merus Collaboration and Expanded ENHANZE Platform Prospects - Yahoo Finance
Is Halozyme Therapeutics Inc. (RV7) stock nearing a technical breakoutJuly 2025 PreEarnings & High Accuracy Investment Entry Signals - newser.com
Using Python tools to backtest Halozyme Therapeutics Inc. strategies2025 Stock Rankings & Real-Time Volume Triggers - newser.com
Why Halozyme Therapeutics Inc. stock is in analyst buy zone - newser.com
What Recent Analyst Upgrades and Partnerships Mean for Halozyme’s Evolving Story and Valuation - Yahoo Finance
Does the Latest Halozyme Partnership Signal Further Upside for the Stock in 2025? - Yahoo Finance
How Halozyme Therapeutics Inc. (RV7) stock reacts to stronger dollarQuarterly Trade Report & Daily Market Momentum Tracking - newser.com
How strong dollar benefits Halozyme Therapeutics Inc. (RV7) stock2025 Market Overview & Fast Moving Stock Trade Plans - newser.com
How Halozyme Therapeutics Inc. (RV7) stock behaves in tightening cyclesEarnings Risk Report & Low Risk Profit Maximizing Plans - newser.com
Will Halozyme Therapeutics Inc. stock see PE expansionJuly 2025 Outlook & Daily Growth Stock Investment Tips - newser.com
Goldman Sachs Maintains Halozyme Therapeutics (HALO) Neutral Recommendation - MSN
Halozyme Therapeutics expands portfolio with Elektrofi acquisition - Traders Union
How Halozyme Therapeutics Inc. (RV7) stock performs in volatility spikesWeekly Trade Review & Detailed Earnings Play Alerts - newser.com
[S-8] HALOZYME THERAPEUTICS, INC. Employee Benefit Plan Registration | HALO SEC FilingForm S-8 - Stock Titan
What drives Halozyme Therapeutics Inc stock priceVolume Profile Analysis & High Return Capital Gain - earlytimes.in
Goldman Sachs Raises Price Target for Halozyme Therapeutics (HAL - GuruFocus
Halozyme Therapeutics Acquires Elektrofi for $750M - Contract Pharma
Halozyme Therapeutics Completes Elektrofi Acquisition - MarketScreener
Halozyme completes acquisition of Elektrofi for $750 million By Investing.com - Investing.com Nigeria
Halozyme completes acquisition of Elektrofi for $750 million - Investing.com
Halozyme completes acquisition of Elektrofi, expanding breadth of offerings in drug delivery - MarketScreener
Halozyme (NASDAQ: HALO) buys Elektrofi for $750M, targeting Hypercon royalties by 2030 - Stock Titan
Halozyme Therapeutics, Inc. completed the acquisition of Elektrofi, Inc. - MarketScreener
Merus and Halozyme partner on subcutaneous cancer drug delivery By Investing.com - Investing.com Nigeria
Halozyme stock price target raised to $56 from $54 at Goldman Sachs - Investing.com
Merus N.V. and Halozyme Therapeutics, Inc. Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab - MarketScreener
Merus, Halozyme Partner to Develop Subcutaneous Formulation of Petosemtamab - Contract Pharma
Merus and Halozyme link up on petosemtamab development - The Pharma Letter
Merus Licenses ENHANZE Drug Delivery Technology Of Halozyme Therapeutics - Nasdaq
Halozyme (HALO) Enters Collaboration Agreement with Merus - GuruFocus
Merus and Halozyme enter global collaboration and license agreement to develop subcutaneous formulation of Petosemtamab - MarketScreener
Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab - Merus
Merus and Halozyme partner on subcutaneous cancer drug delivery - Investing.com
Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab – Company AnnouncementFT.com - Financial Times
Merus (MRUS) and Halozyme (HALO) license ENHANZE to develop subcutaneous petosemtamab - Stock Titan
Will Halozyme Therapeutics Inc. price bounce be sustainablePortfolio Performance Summary & Community Driven Trade Alerts - newser.com
Halozyme Therapeutics Inc (HALO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Halozyme Therapeutics Inc 주식 (HALO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Torley Helen | PRESIDENT AND CEO |
Nov 11 '25 |
Option Exercise |
8.11 |
20,000 |
162,200 |
753,719 |
| Torley Helen | PRESIDENT AND CEO |
Nov 12 '25 |
Option Exercise |
8.11 |
20,000 |
162,200 |
753,719 |
| Torley Helen | PRESIDENT AND CEO |
Nov 12 '25 |
Sale |
70.55 |
20,000 |
1,410,990 |
733,719 |
| Torley Helen | PRESIDENT AND CEO |
Nov 11 '25 |
Sale |
69.13 |
20,000 |
1,382,600 |
733,719 |
| Torley Helen | PRESIDENT AND CEO |
Nov 10 '25 |
Sale |
68.72 |
20,000 |
1,374,339 |
733,719 |
| Connaughton Bernadette | Director |
Nov 10 '25 |
Sale |
68.48 |
2,000 |
136,960 |
42,952 |
| Torley Helen | PRESIDENT AND CEO |
Oct 01 '25 |
Option Exercise |
8.11 |
20,000 |
162,200 |
753,719 |
| Torley Helen | PRESIDENT AND CEO |
Oct 03 '25 |
Option Exercise |
8.11 |
20,000 |
162,200 |
753,719 |
| Torley Helen | PRESIDENT AND CEO |
Oct 02 '25 |
Option Exercise |
8.11 |
20,000 |
162,200 |
753,719 |
| Torley Helen | PRESIDENT AND CEO |
Oct 01 '25 |
Sale |
75.35 |
20,000 |
1,507,024 |
733,719 |
0.76%
2.16%
자본화:
|
볼륨(24시간):